Research programme: hepatitis B therapeutics - Assembly Biosciences/Indiana University

Drug Profile

Research programme: hepatitis B therapeutics - Assembly Biosciences/Indiana University

Alternative Names: Antiviral therapeutics - Assembly Biosciences; Core Protein Allosteric Modulators; CpAMs

Latest Information Update: 26 Sep 2016

Price : $50

At a glance

  • Originator Indiana University
  • Developer Assembly Biosciences; Indiana University
  • Class Small molecules
  • Mechanism of Action Viral core protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatitis B

Most Recent Events

  • 26 Sep 2016 Assembly Biosciences plans a phase Ia/Ib trial for Hepatitis B infection in New Zealand (PO) (NCT02908191)
  • 13 Apr 2016 Pharmacodynamic and pharmacokinetic data presented at the International Liver Congress (ILC-2016) ,
  • 11 Jul 2014 Ventrus Biosciences has merged with Assembly Pharmaceuticals to form Assembly Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top